| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Hepatitits Be Antigen
MessageSendout, Mayo test code: EAG
Test Code
LAB908
Alias/See Also
HBeAg
Hepatitis Be Ag
HBe Ag
HBe antigen
Hepatitis Be antigen
EAG
Hepatitis Be Ag
HBe Ag
HBe antigen
Hepatitis Be antigen
EAG
CPT Codes
87350
Preferred Specimen
1 mL serum from a gold serum gel tube
Patient Preparation
For 24 hours before specimen collection do not take multivitamins or dietary supplements containing biotin (vitamin B7), which is commonly found in hair, skin, and nail supplements and multivitamins.
Minimum Volume
0.5 mL
Other Acceptable Specimens
Red tube
Instructions
1. Centrifuge blood collection tube per collection tube manufacturer's instructions (eg, centrifuge and aliquot within 2 hours of collection for BD Vacutainer tubes).
2. Aliquot serum into plastic vial.
2. Aliquot serum into plastic vial.
Transport Container
Plastic vial
Transport Temperature
Frozen
Specimen Stability
Frozen (preferred): 25 days
Refrigerated: 7 days
Ambient: 24 hours
Refrigerated: 7 days
Ambient: 24 hours
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis: Reject
Gross lipemia: Reject
Gross icterus: Reject
Plasma
Gross lipemia: Reject
Gross icterus: Reject
Plasma
Methodology
Immunoassay (IA)
FDA Status
Approved
Setup Schedule
Monday through Saturday
Report Available
1-3 days
Limitations
Biotin (vitamin B7) is a common ingredient in multivitamins and dietary supplements to enhance hair, nail, and skin growth. Biotin can interfere with the assay performance and cause possible false-negative hepatitis Be antigen (HBeAg) and false-positive anti-HBe results. Patients should be instructed to stop taking such multivitamins and dietary supplements for at least 24 hours prior to blood collection.
Disappearance of HBeAg or appearance of anti-HBe in serum does not completely rule-out chronic hepatitis B carrier state or infectivity.
Performance characteristics of this assay have not been established in patients under the age of 2 or in populations of immunocompromised or immunosuppressed patients. This assay is not licensed by US Food and Drug Administration for testing cord blood specimens or screening donors of blood, plasma, human cell, or tissue products.
Performance characteristics have not been established for the following specimen characteristics:
-Grossly icteric (total bilirubin level >20 mg/dL)
-Grossly lipemic (triolein level >3000 mg/dL)
-Grossly hemolyzed (hemoglobin level >61 mg/dL)
-Specimen containing particulate matter
Disappearance of HBeAg or appearance of anti-HBe in serum does not completely rule-out chronic hepatitis B carrier state or infectivity.
Performance characteristics of this assay have not been established in patients under the age of 2 or in populations of immunocompromised or immunosuppressed patients. This assay is not licensed by US Food and Drug Administration for testing cord blood specimens or screening donors of blood, plasma, human cell, or tissue products.
Performance characteristics have not been established for the following specimen characteristics:
-Grossly icteric (total bilirubin level >20 mg/dL)
-Grossly lipemic (triolein level >3000 mg/dL)
-Grossly hemolyzed (hemoglobin level >61 mg/dL)
-Specimen containing particulate matter
Reference Range
Included with report
Clinical Significance
Determining the presence or absence of detectable hepatitis B e antigen in monitoring infection status of individuals with chronic hepatitis B
Determining infectivity of hepatitis B virus (HBV) carriers
Monitoring serologic response of chronically HBV-infected patients receiving antiviral therapy
Determining infectivity of hepatitis B virus (HBV) carriers
Monitoring serologic response of chronically HBV-infected patients receiving antiviral therapy
Performing Laboratory
Mayo Clinic Laboratories, Rochester, Minnesota
Additional Information
Hepatitis B e Antigen, Serum
